ArriVent BioPharma, Inc.

Contributing Author

Recent Articles by ArriVent BioPharma, Inc.

Jul-21	ArriVent's Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026 AVBP GlobeNewswire
Jul-01	ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants AVBP GlobeNewswire
Jul-01	ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants AVBP GlobeNewswire
Jun-23	ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study AVBP GlobeNewswire
Jun-20	ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC AVBP GlobeNewswire
May-12	ArriVent BioPharma Reports First Quarter 2025 Financial Results AVBP GlobeNewswire